Drug Profile


Alternative Names: Epafipase; PAF-AH; Pafase; Platelet-activating factor acetylhydrolase; Recombinant human platelet-activating-factor acetylhydrolase; rPAF-AH; SUN Y7016

Latest Information Update: 08 Mar 2004

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ICOS Corporation
  • Class Anti-infectives; Anti-inflammatories
  • Mechanism of Action Platelet activating factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Acute enterocolitis; Adult respiratory distress syndrome; Allergic asthma; Inflammatory bowel diseases; Pancreatitis; Reperfusion injury; Sepsis; Type 1 diabetes mellitus

Most Recent Events

  • 08 Mar 2004 A study has been added to the adverse events and Bacterial Infections therapeutic trials sections
  • 23 Dec 2002 Discontinued - Phase-I for Sepsis in Japan (Injection)
  • 23 Dec 2002 Discontinued - Phase-II for Adult respiratory distress syndrome in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top